Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Latest From Teva Pharmaceutical Industries Ltd.

US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar

Bookmark
  • Analysis
By Vibha Ravi

Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect

Commercial Sales & Earnings

Stock Watch: Defeat Is The Mother Of Reinvention

Bookmark
  • Opinion
By Andy Smith

Companies that are successful do not need to change their name, therapeutic area or product focus.

Stock Watch Business Strategies

Quick Listen: Scrip's Five Must-Know Things

Bookmark
  • News
By Ian Haydock

In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.

Clinical Trials Commercial

Zydus Looks To NASH Trials In Turkey, gVascepa Launch In The US

Bookmark
  • Analysis
By Vibha Ravi

Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter

Commercial Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • ABIC Marketing Limited
    • AbZ-Pharma
    • Auspex Pharmaceuticals, Inc. (Imphar AG)
    • Barr Pharmaceuticals
    • Bentley Pharmaceuticals
    • BioGeneriX AG
    • BioAssets Development Corporation
    • Cephalon, Inc. (Arana Therapeutics (Peptech and EvoGenix)
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • CT Arzneimittel GmbH
    • Gecko Health Innovations
    • IVAX Corporation
    • Labrys Biologics
    • Mepha
    • MicroDose Therapeutx Inc.
    • Neose Technologies, Inc.
    • NuPathe, Inc.
    • PLIVA HRVATSKA d.o.o.
    • ratiopharm Group
    • Sicor Biotech
    • Representaciones e Investigaciones Médicas, S.A. de C.V.
    • Taiyo Pharmaceutical Industry Co. Ltd.
    • Teva Branded Pharmaceutical Products, R&D Inc.
    • Teva Women's Health, Inc.
    • Actavis Generics
    • Anda, Inc.
    • Uteron Pharma S.P.R.L.
    • Teva Takeda Yakuhin Ltd.
    • Teva Takeda Pharma Ltd.
    • Teva Neuroscience, Inc.
    • Teva Pharmaceuticals USA, Inc.
    • Zeneus Pharma
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By